Abstract
Once the diagnosis of a particular type of cancer has been established, the physicians need to know the aggressiveness of the tumor in order to decide which treatments should be applied. The aggressiveness of the malignant tumor is evaluated by the clinic (e.g., growth rate or given symptoms), by laboratory/image data (e.g., presence of tumor markers in serum, local/distant extension evaluated by CAT scan), and by histopathology (e.g., tumor size, tumor subtype, nuclear grade, lymph node invasion). In the last few years, molecular markers are progressively being incorporated in order to better define the tumor aggressiveness and the treatment options for a particular cancer, and more importantly, for a particular patient. Prognostic factors are those measurements available at the time of diagnosis or surgery that are associated with disease-free survival (DFS) or overall survival (OS) (Clark 1999). In a strict sense, these factors should be evaluated in the absence of systemic adjuvant therapy which is often difficult to achieve. On the other hand, predictive factors are those measurements indicating the response to a particular treatment. Predictive factors may also be useful in the prognosis, e.g., the presence of estrogen receptor (ER) a and progesterone receptor (PR) predicts the responsiveness to tamoxifen in breast cancer patients and these receptors are also associated with a better prognosis. However, sometimes prognostic and predictive factors are not associated, for example, lymph node invasion is useful for disease prognosis but is not associated with the response to a particular therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andersen J, Skovbon H, Poulsen H (1989) Immunocytochemical determination of the estrogenregulated protein Mr 24,000 in primary breast cancer and response to endocrine therapy. Eur J Cancer Clin Oncol 25:641–643
Assimakopoulou M, Sotiropoulo-Bonikou G, Maraziotis T, Varakis I (1997) Prognostic significance of hsp-27 in astrocytic brain tumors: an immunohistochemical study. Anticancer Res 17:2677–2682
Bielka H, Hoinkis G, Oesterreich S, Stahl J, Benndorf R (1994) Induction of the small stress protein, hsp25, in Ehrlich ascites carcinoma cells by anticancer drugs. FEBS Lett 343:165–167
Cano A, Coffer AI, Adatia R, Millis R, Rubens RD, King RJB (1986) Histochemical studies with an estrogen-regulated protein in human breast tumors. Cancer Res 46:6475–6480
Ciocca DR, Elledge R (2000) Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13:1–10
Ciocca DR, Vargas Roig LM (1997) Heat shock proteins and drug resistance in breast cancer. In: Bernai SD (ed) Drug resistance in oncology. Marcel Dekker, New York, pp 167-19.
Ciocca DR, Adams DJ, Edwards DP, Bjercke RJ, McGuire WL (1983) Distribution of an estrogeninduced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells. Cancer Res 43:1204–1210
Ciocca DR, Puy LA, Edwards DP, Adams DJ, McGuire WL (1985) The presence of an estrogenregulated protein detected by monoclonal antibody in abnormal human endometrium. J Clin Endocrinol Metab 60:137–143
Ciocca DR, Puy LA, Lo Castro G, (1986) Localization of an estrogen-responsive protein in the human cervix during menstrual cycle, pregnancy, and menopause and in abnormal cervical epithelia without atypia. Am J Obst Gynecol 155:1090–1096
Ciocca DR, Stati AO, Fasoli LC (1989) Study of estrogen receptor, progesterone receptor, and the estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and cervix. Cancer Res 49:4298–4304
Ciocca DR, Stati AO, Amprino de Castro MM (1990) Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue. Breast Cancer Res Treat 16:243–251
Ciocca DR, Lo Castro G, Alonio LV, Cobo MF, Lotfi H, Teyssié A (1992) Effect of human papillomavirus infection on estrogen receptor and heat shock protein hsp27 phenotype in human cervix and vagina. Int J Gynecol Pathol 11:113–121
Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SAW (1993) Biological and clinical implications of heat shock protein 27000 (hsp27): a review. J Natl Cancer Inst 85:1558–1570
Ciocca DR, Green S, Elledge RM, Clark GM, Pugh R, Ravdin P, Lew D, Martino S, Osborne CK (1998) Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin Cancer Res 5:1263–1266
Clark GM (1999) Prognostic and predictive factors for primary breast cancer. Proc Am Soc Clin Oncol, 35th Annu Meet, 15-18 May 1999, Atlanta, Georgia, pp 205–220.
Damstrup L, Andersen J, Kufe DW, Hayes DF, Skovgaard Poulsen H (1992) Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Ann Oncol 3:71–77
Dressier LG, Ramzy I, Sledge GW, McGuire WL (1986) A new marker of maturation in the cervix: the estrogen-regulated 24K protein. Obst Gynecol 68:825–831
Edwards DP, Adams DJ, McGuire WL (1981) Estradiol stimulates synthesis of a major intracellular protein in human breast cancer cell line (MCF-7). Breast Cancer Res Treat 1:209–223
Gago FE, Tello OM, Diblasi AM, Ciocca DR (1998) Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients. J Steroid Biochem Mol Biol 67:431–437
Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L (1995) Biologic markers of invasive pituitary adenomas involving the spenoid sinus. Modern Pathol 8:160–164
Garrido C, Mehlen P, Fromentin A, Hammann A, Assem M, Arrigo A-P, Chauffert B (1996) Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. The doxorubicin-protecting effect of Hsp27. Eur J Biochem 237:653–659
Garrido C, Ottavi P, Fromentin A, Hammann A, Arrigo A-P, Chauffert B, Mehlen P (1997) Hsp27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 57:2661–2667
Geisler JP, Geisler HE, Tammela J, Wiemann MC, Zhou Z, Miller GA, Crabtree W (1998) Heat shock protein 27: an independent prognostic indicator of survival in patients with epithelial ovarian carcinoma. Gynecol Oncol 69:14–16.
Geisler JP, Geisler HE, Tammela J, Miller GA, Weimann MC, Zhou Z (1999) A study of heat shock protein 27 in endometrial carcinoma. Gynecol Oncol 72:347–350
Gotthardt R, Neininger A, Gaestel M (1996) The anti-cancer drug cisplatin induces hsp25 in Ehrlich ascites tumor cells by a mechanism different from transcriptional stimulation influencing predominantly hsp25 translation. Int J Cancer 66:790–795
Hanash SM, Kuick R, Strahler J, Richardson B, Reaman G, Stoolman L, Hanson C, Nichols D, Tueche HJ (1989) Identification of a cellular polypeptide that distinguishes between acute lymphoblastic leukemia in infants and in older children. Blood 73:527–532
Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SAW (1999) Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 56:187–196
Harrison JD, Morris DL, Ellis IO, Jones JA, Jackson I (1989) The effect of tamoxifen and estrogen receptor status on survival in gastric carcinoma. Cancer 64:1007–1010
Hettinga JVE, Lemstra W, Meijer C, Los G, de Vries EGE, Konings AWT, Kampinga HH (1996) Heat-shock protein expression in cisplatin-sensitive and-resistant human tumor cells. Int J Cancer 67:800–807
Hitotsumatsu T, Iwaki T, Fukui M, Tateishi J (1996) Distinctive immunohistochemical profiles of small heat shock proteins (heat shock protein 27 and αB-crystallin) in human brain tumors. Cancer 77:352–361
Hsu P-L, Hsu S-M (1998) Abundance of heat-shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin’s disease. Cancer Res 58:5507–5513
Huot J, Houle F, Spitz DR, Landry J (1996) Hsp27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress. Cancer Res 56:273–279
Hurlimann J, Gebhard S, Gomez F (1993) Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23:239–248
Ito T, Kawabe R, Kurasono Y, Hara M, Kitamura H, Fujita K, Kanisawa M (1998) Expression of heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study. J Oral Pathol Med 27:18–22
Kamishima T, Fukuda T, Usuda H, Takato H, Iwamoto H, Kaneko H (1997) Carcinosarcoma of the urinary bladder: expression of epithelial markers and different expression of heat shock proteins between epithelial and sarcomatous elements. Pathol Int 47:166–173
Kasimir-Bauer S, Ottinger H, Meusers P, Beelen DW, Brittinger G, Seeber S, Scheulen ME (1998) In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 26:1111–1117
Kawanishi K, Shiozaki H, Doki Y, Sakita I, Inoue M, Yano M, Tsujinaka T, Shamma A, Monden M, Sanjay TW (1999) Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus. Cancer 85:1649–1657
Khalid H, Tsutsumi K, Yamashita H, Kishikawa M, Yasunaga A, Shibata S (1995) Expression of the small heat shock protein (hsp) 27 in human astrocytomas correlates with histologic grades and tumor growth fractions. Cell Mol Neurobiol 15:257–268
Khan W, McGuirt JP, Sens MA, Sens DA, Todd JH (1996) Expression of heat shock protein 27 in developing and adult human kidney. Toxicol Lett 84:69–79
King K-L, Li AF-Y, Chau G-Y, Chi C-W, Wu C-W, Huang C-L, Lui W-Y (2000) Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer 88:2464–2470
Langdon SP, Rabiasz GJ, Hirst GL, King RJB, Hawkins RA, Smyth JF, Miller WR (1995) Expression of the heat shock protein hsp27 in human ovarian cancer. Clin Cancer Res 1:1603–1609
Lavoie JN, Gingras-Breton G, Tanguay RM, Landry J (1993) Induction of Chinese hamster hsp27 gene expression in mouse cells confers resistance to heat shock. Hsp27 stabilization of the microfilament organization. J Biol Chem 268:3420–3429
Love S, King RJB (1994) A 27kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 69:743–748
Lowe J, McDermott H, Pike I, Spendlove I, Landon M, Mayer RJ (1992) Alpha B crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. J Pathol 166:61–68
Madersbacher S, Gröbl M, Kramer G, Dirnhofer S, Steiner GE, Marberger M (1998) Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment. Prostate 37:174–181
McGuire WL, Dressier LG, Sledge GW, Ramzy I, Ciocca DR (1986) An estrogen-regulated protein in normal and malignant human endometrium. J Steroid Biochem 24:155–159
Navarro D, Cabrera JJ, Falcón O, Jiménez P, Ruiz A, Chirino R, López A, Rivero JF, DÃaz-Chico JC, DÃaz-Chico BN (1989) Monoclonal antibody characterization of progesterone receptors, estrogen receptors and the stress-responsive protein of 27kDa (srp27) in human uterine leiomyoma. J Steroid Biochem 34:491–498
Navarro D, Cabrera JJ, León L, Chirino R. Fernández L, López A, Rivero JF, Fernández P, Falcon O, Jiménez P, Pestano J, DÃaz-Chico JC, DÃaz-Chico BN (1992) Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness. J Steroid Biochem Mol Biol 41:589–596
Oesterreich S, Weng C-H, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SAW (1993) The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 53:4443–4448
Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SAW (1996) The small heat shock protein Hsp27 is not an independent prognostic marker in axillary lymph node-negative breast cancer. Clin Cancer Res 2:1199–1206
Pinder SE, Balsitis M, Ellis 10, Landon M, Mayer RJ, Lowe J (1994) The expression of alpha B-crystallin in epithelial tumours: a useful tumour markeroc J Pathol 174:209–215
Puy LA, Lo Castro G, Olcese JE, Lotfi HO, Brandi HR, Ciocca DR (1989) Analysis of a 24-kiladalton (KD) protein in the human uterine cervix during abnormal growth. Cancer 64:1067–1073
Richards EH, Hickey E, Weber L, Masters JRW (1996) Effect of overexpression of the small heat shock protein hsp27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56:2446–2451
Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske M, Arrigo AP, Buchner J, Gaestel M (1999) Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 274:18947–18956
Salami A, Cotter TG (1996) Heat shock proteins increase resistance to apoptosis. Exp Cell Res 223:163–170
Schneider J, Jimenez E, Marenbach K, Marx D, Meden H (1998) Co-expression of the mdrl gene and hsp27 in human ovarian cancer. Anticancer Res 18:2967–2972
Seymour L, Bezwoda WR, Meyer K (1990) Tumor factors predicting for prognosis in metastatic breast cancer. Cancer 66:2390–2394
Storm FK, Mahvi DM, Gilchrist KW (1993) Hsp-27 has no diagnostic or prognostic significance in prostate or bladder cancers. Urology 42:379–382
Strahler JR, Kuick R, Hanash SM (1991) Diminished phosphorylation of a heat shock protein (Hsp 27) in infant acute lymphoblastic leukemia. Biochem Biophys Res Commun 175:134–142
Takashi M, Katsuno S, Sakata T, Ohshima S, Kato K (1998) Different concentrations of two small stress proteins, ocB crystallin and HSP27 in human urological tumor tissues. Urol Res 26:395–399
Têtu B, Lacasse B, Bouchard H-L, Lagacé R, Huot J, Landry J (1992) Prognostic influence of HSP-27 expression in malignant fibrous histiocytoma: a clinicopathological and immunohistochemical study. Cancer Res 52:2325–2328
Têtu B, Brisson J, Landry J, Huot J (1995) Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study. Breast Cancer Res Treat 36:93–97
Thomas SA, Brown IL, Hollins GW, Hocken A, Kirk D, King RJB, Leake RE (1996) Detection and distribution of heat shock proteins 27 and 90 in human benign and malignant prostatic tissue. Br J Urol 77:367–372
Thor A, Benz C, Moore II D, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA (1991) Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 83:170–178
Ungar DR, Hailat N, Strahler JR, Kuick RD, Brodeur GM, Seeger RC, Reynolds CP, Hanash SM, Sanjay TW (1994) Hsp27 expression in neuroblastoma: correlation with disease stage. J Natl Cancer Inst 86:780–784
Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R (1997) Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79:2336–2344
Vargas SO, Leslie KO, Vacek PM, Socinski MA, Weaver DL (1998) Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma. Cancer 82:1495–1500
Vargas-Roig LM, Lotfi H, Olcese JE, Lo Castro G, Ciocca DR (1993) Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res 13:2457–2464
Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR (1998) Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer (Pred Oncol) 79:468–475
Wachsberger PR, Landry J, Storck C, Davis K, O’Hara MD, Owen CS, Leeper DB, Coss RA (1997) Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 levels and are resistant to cisplatin. Int J Hyperthermia 13:251–255
Xiao K, Liu W, Qu S, Sun H, Tang J (1996) Study of heat shock protein HSP90 alpha, HSP70 mRNA expression in human acute leukemia cells. J Tongji Med Univ 16:212–216
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ciocca, D.R., Vargas-Roig, L.M. (2002). Hsp27 as a Prognostic and Predictive Factor in Cancer. In: Arrigo, AP., Müller, W.E.G. (eds) Small Stress Proteins. Progress in Molecular and Subcellular Biology, vol 28. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56348-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-56348-5_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62708-8
Online ISBN: 978-3-642-56348-5
eBook Packages: Springer Book Archive